New EMA conflicts of interests policy could curtail patient expert advice, says EFPIA
This article was originally published in Scrip
The European Medicines Agency is toughening its conflicts of interests policy to further ensure that its scientific experts do not have links to the pharmaceutical industry that affect their impartiality. However, the industry is concerned that a lack of clarity in the new policy may end up in a shortage of patient experts who are able to "feedback" to either the agency or pharmaceutical companies.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.